Insider Selling: Urogen Pharma (NASDAQ:URGN) Insider Sells $37,383.32 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 871 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the sale, the insider directly owned 59,882 shares of the company’s stock, valued at approximately $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, August 20th, Mark Schoenberg sold 60,677 shares of Urogen Pharma stock. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85.
• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $40.00, for a total value of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total value of $350,100.00.

Urogen Pharma Trading Up 0.2%

Shares of NASDAQ URGN opened at $42.31 on Friday. Urogen Pharma has a twelve month low of $15.86 and a twelve month high of $50.81. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -21.37 and a beta of 1.57. The business has a 50 day simple moving average of $43.33 and a 200-day simple moving average of $31.53.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. As a group, equities analysts predict that Urogen Pharma will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Urogen Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Osaic Holdings Inc. boosted its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Urogen Pharma during the second quarter valued at about $66,000. Russell Investments Group Ltd. boosted its stake in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after buying an additional 3,125 shares in the last quarter. Quantbot Technologies LP acquired a new position in Urogen Pharma during the second quarter worth about $78,000. Finally, Tower Research Capital LLC TRC grew its holdings in Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after acquiring an additional 5,571 shares during the period. Institutional investors own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on URGN shares. HC Wainwright raised their price target on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Guggenheim raised their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Jefferies Financial Group restated a “buy” rating and issued a $56.00 target price on shares of Urogen Pharma in a research note on Thursday. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Finally, Oppenheimer raised their price target on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.